The continuation of fast and successful adjustment of legislation to EU standards increases investors' interest and currently the most attractive prospect is the acquisition of the drugs company Pliva, D&B said in a report.
It recalled that the screening of the policy chapter on financial control was completed in late June and that the state secretary for development strategy and coordination with EU funds, Martina Dalic, said that Croatian legislation regulating financial control was quite adjusted to EU legal provisions although some changes still had to be made.
Big progress has been noted in recent years in internal auditing and work is also being done in external control, D&B said, adding that Croatia was also working on the establishment of an office for cooperation with the European antifraud office OLAF.
The report noted that Iceland's Actavis and the US pharmaceutical company Barr were currently bidding for Pliva.
Croatia's credit rating for August remains DB4a, which it was first given in June, up from the previous DB4c, thanks to the successful completion of the first policy chapter in entry negotiations with the EU.
With its August rating Croatia has moved ahead of Romania, which has a DB4b, and reached Bulgaria. This rating ranks Croatia tenth on a list of 25 countries in transition.
D&B raised Croatia's rating twice this year, in February and in June. In February, the rating was raised from DB4d to DB4c after five years.